INDV (Indivior Pharmaceuticals) Piotroski F-Score: 4 (As of Jun. 24, 2026) — 20% Below Median


INDV Indivior Pharmaceuticals Inc INDV
75 GF Score
Price $41.48
GF Value $22.99
Valuation Significantly Overvalued
! 6 Warning Signs
View Full Analysis

What is Indivior Pharmaceuticals Piotroski F-Score?

Indivior Pharmaceuticals INDV +3.80% 75 Piotroski F-Score is 4 as of Jun. 24, 2026, which is 20% below its 10-year median of 5.00. GuruFocus rates INDV with a GF Score™ of 75/100 and a GF Value™ of $22.99 (Significantly Overvalued). The stock has 6 warning signs investors should review. Among 981 Drug Manufacturers companies, Indivior Pharmaceuticals ranks worse than 60.86% on this metric.

The zones of discrimination were as such:

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

Indivior Pharmaceuticals has an F-score of 4 indicating the company's financial situation is typical for a stable company.

The historical rank and industry rank for Indivior Pharmaceuticals's Piotroski F-Score or its related term are showing as below:

INDV' s Piotroski F-Score Range Over the Past 10 Years
Min: 1   Med: 5   Max: 8
Current: 4

During the past 13 years, the highest Piotroski F-Score of Indivior Pharmaceuticals was 8. The lowest was 1. And the median was 5.

Indivior Pharmaceuticals  (NAS:INDV) Piotroski F-Score Explanation

The developer of the system is Joseph D. Piotroski is relatively unknown accounting professor who shuns publicity and rarely gives interviews.

He graduated from the University of Illinois with a B.S. in accounting in 1989, received an M.B.A. from Indiana University in 1994. Five years later, in 1999, after earning a Ph.D. in accounting from the University of Michigan, he became an associate professor of accounting at the University of Chicago.

In 2000, he wrote a research paper called "Value Investing: The Use of Historical Financial Statement Information to Separate Winners from Losers" (pdf).

He wanted to see if he can develop a system (using a simple nine-point scoring system) that can increase the returns of a strategy of investing in low price to book (referred to in the paper as high book to market) value companies.

What he found was something that exceeded his most optimistic expectations.

Buying only those companies that scored highest (8 or 9) on his nine-point scale, or F-Score as he called it, over the 20 year period from 1976 to 1996 led to an average out-performance over the market of 13.4%.

Even more impressive were the results of a strategy of investing in the highest F-Score companies (8 or 9) and shorting companies with the lowest F-Score (0 or 1).

Over the same period from 1976 to 1996 (20 years) this strategy led to an average yearly return of 23%, substantially outperforming the average S&P 500 index return of 15.83% over the same period.


Indivior Pharmaceuticals Piotroski F-Score Related Terms


Indivior Pharmaceuticals Piotroski F-Score Historical Data

* Premium members only.

The historical data trend for Indivior Pharmaceuticals's Piotroski F-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Indivior Pharmaceuticals Piotroski F-Score Chart

Indivior Pharmaceuticals Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Piotroski F-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only 7.00 3.00 2.00 6.00 3.00

Indivior Pharmaceuticals Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Piotroski F-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 5.00 7.00 7.00 3.00 4.00

INDV vs AMRX, KNSA, LQDA: Piotroski F-Score Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Indivior Pharmaceuticals's Piotroski F-Score, along with its competitors' market caps and Piotroski F-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Indivior Pharmaceuticals Piotroski F-Score vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Indivior Pharmaceuticals's Piotroski F-Score distribution charts can be found below:

* The bar in red indicates where Indivior Pharmaceuticals's Piotroski F-Score falls into.


INDV
75GF Score
Indivior Pharmaceuticals Inc INDV
Piotroski F-Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

How is the Piotroski F-Score calculated?

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Mar26) TTM:Last Year (Mar25) TTM:
Net Income was 18 + 42 + 102 + 89 = $251 Mil.
Cash Flow from Operations was 158 + -39 + -221 + -9 = $-111 Mil.
Revenue was 302 + 314 + 358 + 317 = $1,291 Mil.
Gross Profit was 250 + 231 + 291 + 277 = $1,049 Mil.
Average Total Assets from the begining of this year (Mar25)
to the end of this year (Mar26) was
(1375 + 1452 + 1416 + 1201 + 1197) / 5 = $1328.2 Mil.
Total Assets at the begining of this year (Mar25) was $1,375 Mil.
Long-Term Debt & Capital Lease Obligation was $500 Mil.
Total Current Assets was $667 Mil.
Total Current Liabilities was $779 Mil.
Net Income was -97 + 22 + 21 + 47 = $-7 Mil.

Revenue was 299 + 307 + 299 + 266 = $1,171 Mil.
Gross Profit was 220 + 241 + 251 + 222 = $934 Mil.
Average Total Assets from the begining of last year (Mar24)
to the end of last year (Mar25) was
(1453 + 1535 + 1464 + 1316 + 1375) / 5 = $1428.6 Mil.
Total Assets at the begining of last year (Mar24) was $1,453 Mil.
Long-Term Debt & Capital Lease Obligation was $341 Mil.
Total Current Assets was $883 Mil.
Total Current Liabilities was $1,005 Mil.

*Note: If the latest quarterly/semi-annual/annual total assets data is 0, then we will use previous quarterly/semi-annual/annual data for all the items in the balance sheet.

Profitability

Question 1. Return on Assets (ROA)

Net income before extraordinary items for the year divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

Indivior Pharmaceuticals's current Net Income (TTM) was 251. ==> Positive ==> Score 1.

Question 2. Cash Flow Return on Assets (CFROA)

Net cash flow from operating activities (operating cash flow) divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

Indivior Pharmaceuticals's current Cash Flow from Operations (TTM) was -111. ==> Negative ==> Score 0.

Question 3. Change in Return on Assets

Compare this year's return on assets (1) to last year's return on assets.

Score 1 if it's higher, 0 if it's lower.

ROA (This Year)=Net Income/Total Assets (Mar25)
=251/1375
=0.18254545

ROA (Last Year)=Net Income/Total Assets (Mar24)
=-7/1453
=-0.00481762

Indivior Pharmaceuticals's return on assets of this year was 0.18254545. Indivior Pharmaceuticals's return on assets of last year was -0.00481762. ==> This year is higher. ==> Score 1.

Question 4. Quality of Earnings (Accrual)

Compare Cash flow return on assets (2) to return on assets (1)

Score 1 if CFROA > ROA, 0 if CFROA <= ROA.

Indivior Pharmaceuticals's current Net Income (TTM) was 251. Indivior Pharmaceuticals's current Cash Flow from Operations (TTM) was -111. ==> -111 <= 251 ==> CFROA <= ROA ==> Score 0.

Funding

Question 5. Change in Gearing or Leverage

Compare this year's gearing (long-term debt divided by average total assets) to last year's gearing.

Score 0 if this year's gearing is higher, 1 otherwise.

Gearing (This Year: Mar26)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Mar25 to Mar26
=500/1328.2
=0.37644933

Gearing (Last Year: Mar25)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Mar24 to Mar25
=341/1428.6
=0.23869523

Indivior Pharmaceuticals's gearing of this year was 0.37644933. Indivior Pharmaceuticals's gearing of last year was 0.23869523. ==> Last year is lower than this year ==> Score 0.

Question 6. Change in Working Capital (Liquidity)

Compare this year's current ratio (current assets divided by current liabilities) to last year's current ratio.

Score 1 if this year's current ratio is higher, 0 if it's lower

Current Ratio (This Year: Mar26)=Total Current Assets/Total Current Liabilities
=667/779
=0.85622593

Current Ratio (Last Year: Mar25)=Total Current Assets/Total Current Liabilities
=883/1005
=0.87860697

Indivior Pharmaceuticals's current ratio of this year was 0.85622593. Indivior Pharmaceuticals's current ratio of last year was 0.87860697. ==> Last year's current ratio is higher ==> Score 0.

Question 7. Change in Shares in Issue

Compare the number of shares in issue this year, to the number in issue last year.

Score 0 if there is larger number of shares in issue this year, 1 otherwise.

Indivior Pharmaceuticals's number of shares in issue this year was 128.986. Indivior Pharmaceuticals's number of shares in issue last year was 125. ==> There is larger number of shares in issue this year. ==> Score 0.

Efficiency

Question 8. Change in Gross Margin

Compare this year's gross margin (Gross Profit divided by sales) to last year's.

Score 1 if this year's gross margin is higher, 0 if it's lower.

Gross Margin (This Year: TTM)=Gross Profit/Revenue
=1049/1291
=0.81254841

Gross Margin (Last Year: TTM)=Gross Profit/Revenue
=934/1171
=0.79760888

Indivior Pharmaceuticals's gross margin of this year was 0.81254841. Indivior Pharmaceuticals's gross margin of last year was 0.79760888. ==> This year's gross margin is higher. ==> Score 1.

Question 9. Change in asset turnover

Compare this year's asset turnover (total sales for the year divided by total assets at the beginning of the year) to last year's asset turnover ratio.

Score 1 if this year's asset turnover ratio is higher, 0 if it's lower

Asset Turnover (This Year)=Revenue/Total Assets at the Beginning of This Year (Mar25)
=1291/1375
=0.93890909

Asset Turnover (Last Year)=Revenue/Total Assets at the Beginning of Last Year (Mar24)
=1171/1453
=0.80591879

Indivior Pharmaceuticals's asset turnover of this year was 0.93890909. Indivior Pharmaceuticals's asset turnover of last year was 0.80591879. ==> This year's asset turnover is higher. ==> Score 1.

Evaluation

Piotroski F-Score= Que. 1+ Que. 2+ Que. 3+Que. 4+Que. 5+Que. 6+Que. 7+Que. 8+Que. 9
=1+0+1+0+0+0+0+1+1
=4

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

Indivior Pharmaceuticals has an F-score of 4 indicating the company's financial situation is typical for a stable company.

Frequently Asked Questions Learn more about Piotroski F-Score →
What does a Piotroski F-Score of 4 mean?
Indivior Pharmaceuticals (INDV) has a Piotroski F-Score of 4 as of Jun. 24, 2026. The Piotroski F-score grades a company's business operating strength from 0-9. View historical data on Indivior Pharmaceuticals and its competitors. This is 20% below median its historical median of 5.00. Over the past decade, Indivior Pharmaceuticals' Piotroski F-Score has ranged from 1.00 to 8.00. According to the industry distribution chart, Indivior Pharmaceuticals ranks #597 out of 981 companies in the Drug Manufacturers industry, placing it in the top 60.9%.
Is Indivior Pharmaceuticals' Piotroski F-Score too high?
Indivior Pharmaceuticals' current Piotroski F-Score of 4 is 20% below median its 10-year median of 5.00. Over the past 10 years, this metric has ranged from a low of 1.00 to a high of 8.00. The Drug Manufacturers industry median Piotroski F-Score is 5.00. Indivior Pharmaceuticals' value of 4 is 20% below this industry median. Based on the distribution chart, Indivior Pharmaceuticals ranks #597 out of 981 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Indivior Pharmaceuticals has a GF Score™ of 75/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Indivior Pharmaceuticals' Piotroski F-Score compare to AMRX and KNSA?
According to the Drug Manufacturers industry distribution chart, Indivior Pharmaceuticals ranks #597 out of 981 companies for Piotroski F-Score. This places Indivior Pharmaceuticals in the lower half of its industry. The industry median Piotroski F-Score is 5.00. Indivior Pharmaceuticals' value of 4 is 20% below this benchmark. Historically, Indivior Pharmaceuticals' own Piotroski F-Score has ranged from 1.00 to 8.00 over the past decade. While the company's 10-year median is 5.00 vs. the industry median of 5.00, Indivior Pharmaceuticals has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Piotroski F-Score for a Drug Manufacturers company?
The median Piotroski F-Score among Drug Manufacturers companies is 5.00, based on 981 companies in the industry. Companies in the top quartile (top 25%) have a Piotroski F-Score significantly above this median, while those in the bottom quartile fall well below. However, Piotroski F-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Indivior Pharmaceuticals's current Piotroski F-Score of 4 is 20% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Piotroski F-Score mean?
A high Piotroski F-Score can signal that a stock is expensive relative to its fundamentals. The Piotroski F-score grades a company's business operating strength from 0-9. View historical data on Indivior Pharmaceuticals and its competitors. For the Drug Manufacturers industry, the median Piotroski F-Score is 5.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Indivior Pharmaceuticals's current Piotroski F-Score is 4, which is 20% below median its own 10-year median of 5.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Indivior Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Indivior Pharmaceuticals (INDV) is currently considered Significantly Overvalued. The stock's GF Value™ is $22.99, compared to a current price of $41.48 — trading 80.4% above its estimated fair value. The current Piotroski F-Score is 4, which is 20% below median its 10-year median of 5.00 and 20% below the Drug Manufacturers industry median of 5.00. Indivior Pharmaceuticals' overall GF Score™ is 75/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Piotroski F-Score calculated?
Piotroski F-Score is calculated from a company's financial statements. For Indivior Pharmaceuticals (INDV), the current Piotroski F-Score is 4 as of Jun. 24, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Indivior Pharmaceuticals (INDV) Overvalued in 2026?

Based on GuruFocus' analysis, Indivior Pharmaceuticals stock appears to be overvalued. The current stock price of $41.48 is trading 80.4% above its estimated GF Value™ of $22.99. GuruFocus considers Indivior Pharmaceuticals to be Significantly Overvalued.

Key valuation signals for INDV:

  • Piotroski F-Score: 4 (20% below median its 10-year median of 5.00)
  • GF Value™: $22.99 vs. price of $41.48 (80.4% above fair value)
  • GF Score™: 75/100 with 6 warning signs
  • Industry Position: 20% below the Drug Manufacturers median (#597 of 981)

No single metric tells the full story. See the INDV stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Indivior Pharmaceuticals Business Description

Other Exchanges E7P:Germany
Address 10710 Midlothian Turnpike, Suite 125, North Chesterfield, Richmond, VA, USA, 23235
Indivior Pharmaceuticals Inc is a specialty pharmaceutical company singularly focused on delivering evidence-based treatment and advancing understanding of opioid use disorder (OUD) as a chronic but treatable brain disease. The company derives revenues from customers through the development, manufacture and sale of buprenorphine-based prescription drugs for treatment of opioid dependence and related disorders. The company's products include: Sublocade (buprenorphine extended-release monthly injection), and Suboxone (buprenorphine and naloxone sublingual film).
75GF Score

Get the complete analysis for INDV

Piotroski F-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$41.48
Price
$22.99
GF Value